Details of the Drug Reposition

General Information of This Drug (ID: DM0HXDS)

Drug Name
Pentostatin   DM0HXDS
Synonyms
Coforin; Covidarabine; Deoxycoformycin; Nipent; Oncopent; Vidarbine; Vira A deaminase inhibitor; CL-67310465; CO-Vidarabine; Co-V; Nipent (TN); PD-81565; PD-ADI; Pentostatin (JAN/USAN/INN); (8R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol; (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol; (R)-3-(2-Deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo(4,5-d)(1,3)diazepin-8-ol; 2'-DCF; 2'-Deoxycoformycin; 2'-Dexoycoformycin
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Leukemia DISNAKFL N.A. Approved [1]
Acute graft versus host disease DIS8KLVM 4B24.0 Approved [1]
------------------------------------------------------------------------------------
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Hairy cell leukaemia DISTD2E5 2A82.2 Discontinued in Phase 2 [2]
------------------------------------------------------------------------------------

References

1 Pentostatin FDA Label
2 Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)